We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Nanoparticle Delivery Increases Effectiveness of Anti-Cancer Immunotherapy

By LabMedica International staff writers
Posted on 10 May 2018
A nanoparticle delivery system was used to transport antibody-based immunotherapeutic drugs in trials conducted in cancer cell in vitro cultures and in animal models.

Combination immunotherapy has recently emerged as a powerful cancer treatment strategy. More...
A promising treatment approach is based on the simultaneous administration of antagonistic antibodies to block checkpoint inhibitor receptors, such as anti-programmed cell death‐1 (PD1). Immune checkpoints are regulators of the immune system. These pathways are crucial for self-tolerance, which prevents the immune system from attacking cells indiscriminately.

In this treatment strategy, antibodies targeting checkpoint inhibitor receptors are given together with agonistic antibodies to activate co-stimulatory receptors, such as anti-tumor necrosis factor receptor superfamily member 4 (OX40). OX40's value as a drug target resides primarily in it being transiently expressed after T-cell receptor engagement. It is only upregulated on the most recently antigen-activated T-cells within inflammatory lesions.

Optimal T‐cell activation is achieved when both immunomodulatory agents simultaneously engage T‐cells and promote synergistic pro-activation signaling. However, standard administration of these therapeutics as free antibodies results in suboptimal T‐cell binding events, with only a subset of the T‐cells binding to both PD1 and OX40.

To increase the changes of simultaneous binding of both classes of antibody, investigators at the University of North Carolina (Chapel Hill, USA) developed nanoparticles capable of simultaneous co-delivery of antibodies to PD1 and OX40.

They reported in the April 25, 2018, online edition of the journal Advanced Materials that using these dual immunotherapy nanoparticles (DINP) resulted in improved T‐cell activation, enhanced therapeutic efficacy, and increased immunological memory. They demonstrated that DINP elicited higher rates of T‐cell activation in vitro than free antibodies. Furthermore, they showed in two tumor models that combination immunotherapy administered in the form of DINP was more effective than the same regimen administered as free antibodies.

"Our study suggests that if you are able to present two different therapeutics at the same time to immune cells to help them fight cancer, the effect is greater," said senior author Dr. Andrew Z. Wang, associate professor of radiation oncology at the University of North Carolina. "It is difficult to deliver them at the same time unless you tie them together, and a nanoparticle is one great way to tie the two together."

"Our immune cells have both positive and negative signals, like red lights and green lights," said Dr. Wang. "It is part of the balance of the immune system - if you get too much immune activation, you get autoimmune disease. If you go the other way, the lack of immune suppression can give you tumors. We are studying a combination of treatments that both send green light signals to attack, and to block red light signals."

Related Links:
University of North Carolina


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automated Immunoassay Analyzer
SuperFlex™
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Led by Professor Sherry Chan Kit-wa (middle), the HKUMed research team provides the first large-scale Chinese population evidence to support reviewing Hong Kong’s long-term blood-monitoring requirements for clozapine use. (Photo courtesy of HKUMed)

Study Supports Review of Long-Term Blood-Monitoring Guidelines for Clozapine

Treatment-resistant schizophrenia (TRS) is a severe form of schizophrenia for which clozapine remains the only antipsychotic specifically approved by the U.S. Food and Drug Administration (FDA).... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image

Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil

Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.